$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000140191419000081 Filed on August 14, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.450M	$1.470M	$1.410M
YoY Change	22.88%	4.26%	193.75%
% of Gross Profit
Research & Development	$1.966M	$2.513M	$2.218M
YoY Change	35.93%	13.3%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$3.419M	$3.982M	$3.625M
YoY Change	30.4%	9.87%	655.17%
Operating Profit	-$3.419M	-$3.982M	-$3.625M
YoY Change	30.4%	9.87%	655.76%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$25.47K	$30.00K	$42.63K
YoY Change	-45.95%	-29.62%	-329.54%
Pretax Income	-$3.390M	-$3.950M	-$3.580M
YoY Change	31.91%	10.34%	616.0%
Income Tax
% Of Pretax Income
Net Earnings	-$3.393M	-$3.952M	-$3.582M
YoY Change	31.8%	10.34%	616.43%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$203.2K	-$245.2K	-$313.5K
COMMON SHARES
Basic Shares Outstanding	16.68M shares	16.68M shares	11.42M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.440M	$5.630M	$12.45M
YoY Change	-74.42%	-54.78%	71.96%
Cash & Equivalents	$2.435M	$5.600M	$12.45M
Short-Term Investments
Other Short-Term Assets	$770.0K	$440.0K	$350.0K
YoY Change	40.0%	25.71%
Inventory
Prepaid Expenses	$770.5K	$438.0K
Receivables
Other Receivables	$37.84K	$493.0K
Total Short-Term Assets	$3.243M	$6.562M	$12.82M
YoY Change	-68.11%	-48.82%	57.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.905K	$7.081K	$7.910K
YoY Change	-40.95%	-10.48%	-60.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$632.6K	$692.3K	$660.0K
YoY Change	2.04%	4.89%
Total Long-Term Assets	$638.6K	$699.4K	$660.0K
YoY Change	1.36%	5.97%	3042.86%
TOTAL ASSETS
Total Short-Term Assets	$3.243M	$6.562M	$12.82M
Total Long-Term Assets	$638.6K	$699.4K	$660.0K
Total Assets	$3.882M	$7.261M	$13.48M
YoY Change	-64.06%	-46.14%	65.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$350.0K	$630.0K	$1.270M
YoY Change	-70.83%	-50.39%	92.42%
Accrued Expenses	$1.537M	$1.342M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.889M	$1.974M	$1.270M
YoY Change	57.4%	55.43%	-62.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$183.2K	$203.9K	$0.00
YoY Change	1731.96%		-100.0%
Total Long-Term Liabilities	$183.2K	$203.9K	$0.00
YoY Change	1731.96%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.889M	$1.974M	$1.270M
Total Long-Term Liabilities	$183.2K	$203.9K	$0.00
Total Liabilities	$2.072M	$2.178M	$1.270M
YoY Change	70.93%	71.49%	-68.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$40.20M	-$36.80M
YoY Change
Common Stock	$42.08M	$41.94M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.810M	$5.083M	$12.22M
YoY Change
Total Liabilities & Shareholders Equity	$3.882M	$7.261M	$13.48M
YoY Change	-64.06%	-46.14%	65.4%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$3.393M	-$3.952M	-$3.582M
YoY Change	31.8%	10.34%	616.43%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$3.180M	-$3.020M	-$2.690M
YoY Change	15.64%	12.27%	2345.45%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$450.0K
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	$0.00	$0.00	-$460.0K
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$5.200M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	5.150M	0.000
YoY Change	-100.0%		-100.0%
NET CHANGE
Cash From Operating Activities	-3.180M	-3.020M	-2.690M
Cash From Investing Activities	0.000	0.000	-460.0K
Cash From Financing Activities	0.000	5.150M	0.000
Net Change In Cash	-3.180M	2.130M	-3.150M
YoY Change	9.66%	-167.62%	6200.0%
FREE CASH FLOW
Cash From Operating Activities	-$3.180M	-$3.020M	-$2.690M
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$3.180M	-$3.020M	-$2.680M
YoY Change	15.64%	12.69%	2336.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dare	Adjustments To Additional Paid In Capital Common Stock And Warrants Issued AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued	9157888	USD
CY2017Q3	dare	Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationReverseMergerRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	9900000	USD
CY2017Q3	dare	Business Combination Reverse Merger Unamortized Fair Value Of Stock Options BusinessCombinationReverseMergerUnamortizedFairValueOfStockOptions	3700000	USD
CY2018Q1	dare	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	10000000	USD
	dare	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	1100000	USD
	dare	Increase Decrease In Other Non Current Assets And Deferred Charges IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges	-66160	USD
	dare	Increase Decrease In Other Non Current Assets And Deferred Charges IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges	-79063	USD
CY2018Q2	dare	License Fee LicenseFee	250000	USD
	dare	License Fee LicenseFee	350000	USD
CY2019Q2	dare	License Fee LicenseFee	162500	USD
	dare	License Fee LicenseFee	275000	USD
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	10195653	USD
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	5151702	USD
	dare	Non Cash Lease Expense NonCashLeaseExpense	0	USD
	dare	Non Cash Lease Expense NonCashLeaseExpense	10549	USD
	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2018Q1	dare	Percentage Of Aggregate Commission PercentageOfAggregateCommission	0.03
CY2018Q3	dare	Percentage Of Increase In Annual Base Rent PercentageOfIncreaseInAnnualBaseRent	0.04
CY2019Q2	dare	Reimbursement Of Grant Expenses Receivable ReimbursementOfGrantExpensesReceivable	456484	USD
CY2018Q1	dare	Research And Development Milestone Payment ResearchAndDevelopmentMilestonePayment	75000	USD
CY2019Q2	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0
	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0
	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y10M24D
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001401914
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16683411	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Dare Bioscience, Inc.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	459705	USD
CY2019Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	632118	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	631351	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1341811	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-96728	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-97024	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35791972	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	41942062	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9423	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18547	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	111351	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	209319	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2160	USD
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4298573	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4298573	shares
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5941193	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5941193	shares
CY2018Q4	us-gaap	Assets Assets	7827387	USD
CY2019Q2	us-gaap	Assets Assets	7260932	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	7240023	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	6561546	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6805889	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5630569	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5600000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7559846	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12446524	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6805889	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5630569	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4886678	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1175320	USD
CY2019Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	30333	shares
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3500000.0	shares
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3750833	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11422161	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16683411	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11422161	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16683411	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1143	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	1668	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3609655	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11289018	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4749961	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7794180	USD
CY2019Q2	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	1348159	USD
	us-gaap	Depreciation Depreciation	288	USD
	us-gaap	Depreciation Depreciation	2315	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.13
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-41231	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-296	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1157174	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2460363	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1307379	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2584559	USD
CY2018Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5200000	USD
CY2018Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5187519	USD
CY2019Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q2	us-gaap	Grants Receivable GrantsReceivable	456484	USD
CY2018Q2	us-gaap	Grants Receivable GrantsReceivable	1900000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9739	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	172413	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	288846	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	710459	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-193495	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-75	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-9711	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-259562	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	461982	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	35838	USD
CY2019Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.07
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	34861	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4807544	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6326726	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5151702	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-460200	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	236069	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	55531	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	67595	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	112943	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	42669	USD
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P37M
CY2018Q4	us-gaap	Liabilities Liabilities	1100767	USD
CY2019Q2	us-gaap	Liabilities Liabilities	2177877	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7827387	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7260932	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1091056	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1973929	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10195653	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6300000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-3582170	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11247787	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-3952450	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7004290	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3582170	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11247787	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4742044	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7793884	USD
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	3624796	USD
	us-gaap	Operating Expenses OperatingExpenses	11302157	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	3982451	USD
	us-gaap	Operating Expenses OperatingExpenses	7065522	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3624796	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11302157	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3982451	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7065522	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	27038	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	54076	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	193400	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	241000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	87859	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	116089	USD
CY2019Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	26620	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	53240	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	232000	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	193399	USD
CY2018Q3	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	8873	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	577968	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	692305	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-27485	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-41231	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7917	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-296	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9711	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	203948	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	42626	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	54370	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30001	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	61232	USD
CY2018Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	31037	USD
CY2019Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	493019	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	237403	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	452000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8200	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	403097	USD
CY2019Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	437958	USD
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5200000	USD
	us-gaap	Profit Loss ProfitLoss	-11247787	USD
	us-gaap	Profit Loss ProfitLoss	-7004290	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9396	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7081	USD
	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	224665	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2217622	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3304275	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2512572	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4205963	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	452000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28969767	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36763651	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36800000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2019Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5261250	shares
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	231698	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18547	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	209319	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.23
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.21
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0209
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0258
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	427702	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	21.83
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	70	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	316832	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	698000	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.86
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.75
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1635790	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2016888	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.08
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.40
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	59.48
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	24.55
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.79
CY2019Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
CY2018Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	375000	shares
CY2019Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1037764	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5151702	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5151702	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	13292782	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	15820356	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	12217963	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	6726620	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	3780369	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	5083055	USD
CY2018Q2	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	0	USD
CY2019Q2	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	800000	USD
CY2019Q2	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	789594	USD
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	800000	USD
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	789594	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11422161	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10031249	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16105252	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13776643	shares

Files In Submission

Name	View Source	Status
0001401914-19-000081-index-headers.html	Edgar Link	pending
0001401914-19-000081-index.html	Edgar Link	pending
0001401914-19-000081.txt	Edgar Link	pending
0001401914-19-000081-xbrl.zip	Edgar Link	pending
dare-20190630.xml	Edgar Link	completed
dare-20190630.xsd	Edgar Link	pending
dare-20190630_cal.xml	Edgar Link	unprocessable
dare-20190630_def.xml	Edgar Link	unprocessable
dare-20190630_lab.xml	Edgar Link	unprocessable
dare-20190630_pre.xml	Edgar Link	unprocessable
darebioinlinefullcolorrgb.jpg	Edgar Link	pending
dare_10qx20190630.htm	Edgar Link	pending
exhibit311_20190630.htm	Edgar Link	pending
exhibit312_20190630.htm	Edgar Link	pending
exhibit321_20190630.htm	Edgar Link	pending
exhibit322_20190630.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2019 Q3 Form 10-Q Financial Statement

#000140191419000081 Filed on August 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2019 Q3 Form 10-Q Financial Statement

#000140191419000081 Filed on August 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare